Latest News and Press Releases

BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and...

BELTSVILLE, Md., Dec. 10, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and...

BELTSVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...

BELTSVILLE, Md., Nov. 19, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...

Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-endCash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md.,...

Preclinical data for LNCB74 highlights its potential as therapeutic for treating multiple solid tumor indications; Investigational New Drug (IND) application filing expected by year-endAdditional...

BELTSVILLE, Md., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...

Of the 20 evaluable ovarian cancer patients, there were 5 PRs Of the 43 evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 3 PRs Biomarker data support proposed mechanism...

LNCB74 (B7-H4 ADC) GLP tox studies completed and targeting an IND application by year-endNC410 combo with pembrolizumab ovarian cohort enrollment completedCash of approximately $86.4 million expected...

BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and...